RxDoctor Payments Data

Luis Rivera Rodriguez

Ophthalmology · Mayaguez, PRNPI 1801885249

Payments from drug & device makers

$1,007in general payments, 2019–2025

Across 17 payments — averaging $59.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Puerto Rico Inc$440
  • Amgen$201
  • Mallinckrodt Hospital Products Inc.$125
  • Alcon$52
  • Bausch & Lomb Americas Inc.$50
  • Abbott$47
  • plus $92 from 3 others

What the payments were for

  • Food & beverage$1,007100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon Puerto Rico Inc4$440
Amgen(2 entities)3$201
Mallinckrodt Hospital Products Inc.1$125
Alcon1$52
Bausch & Lomb Americas Inc.2$50
Abbott2$47
AbbVie2$45
Johnson & Johnson Surgical Vision, Inc.1$25
Merck1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,007 in reported general payments places this provider in the 60th percentile of 214 ophthalmology providers in Puerto Rico.

See all ophthalmology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$17,970
Medicare patients
52
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine118$74,306
LumiganBimatoprost267$69,375
Cyclosporine126$33,172
Prednisolone Acetate788$30,646
Fluorometholone288$19,553
Latanoprost1,156$12,757
Brimonidine Tartrate175$11,779
Ofloxacin504$11,010
Alphagan PBrimonidine Tartrate50$10,712
ErythromycinErythromycin Base293$4,500
CombiganBrimonidine Tartrate/Timolol14$3,229
Timolol Maleate261$2,871
Dorzolamide Hcl84$2,497
Pilocarpine Hcl23$1,546
ValacyclovirValacyclovir Hcl16$1,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$45$157,622449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 214 ophthalmology providers in Puerto Rico.

Other ophthalmology in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →